Current Position

Education

• PhD in Toxicology, School of Pharmacy, University of Colorado, Denver, USA (2004)
• MSc by research, Department of Molecular & Cell Biology, University of Aberdeen, UK (1996)
• PGDip in Human Nutrition & Metabolism, Department of Human Nutrition, University of Aberdeen, UK (1994)
• PGDip in Medical & Molecular Genetics, Department of Molecular & Cell Biology, University of Aberdeen, UK (1993)
• BSc in Pure Science, Department of Molecular & Cell Biology, University of Aberdeen, UK (1992)

Research Interests

• Cancer Genetics & Epigenetics
• Experimental & Translational Cancer Therapeutics
• Cancer Biomarkers & Molecular Diagnostics
• Cancer & Nutritional Therapy
• One Health Initiative
• Novel Materials For Biomedical Applications
• Circular Economy
   

Mihalis conducts multidisciplinary research in several areas of academic and industrial interests in the context of: 

A.    Cancer therapeutics with an emphasis in understanding the genetic/epigenetic background in cancer pathophysiology, the development of experimental cancer therapeutics and the role of phytochemicals in clinically relevant adjuvant therapeutic strategies. To these ends, his research aims to determine the role of epigenetic modifications in altering apoptotic gene expression in ways compatible with the anticancer properties of various natural phytochemicals, novel synthetic small molecules and other experimental cancer therapeutic modalities (e.g., hyperthermia) in order to identify key apoptotic targets capable of mediating a therapeutic response; 

B.    One Health Initiative with a particular focus on the effects of climate change, environmental contamination disease emergence/re-emergence in global human health and the role of personalized nutrition as an implementation strategy towards chronic disease prevention.

C.    Circular economy (e.g., waste recycling, food security and quality, etc.) by means of toxicity and safety evaluation as well as assessment of health-promoting properties of sustainable and eco-friendly biomolecules for the development of end user applications and/or niche consumer product formulations. 

D.    Novel engineered materials towards various biomedical applications (e.g., orthopedic implants, drug delivery platforms, etc.) by evaluating their biocompatibility potential and overall functional performance. 
Last, but not least, Mihalis has published over 135 peer reviewed publications in various journals spanning across different scientific fields while his research has been funded by a number of substantial grants from major funding agencies. 

Selected Publications (last 3 years)

A. Cancer Genetics / Epigenetics, Biomarkers & Therapeutics

1. Mitsiogianni M, Trafalis DT, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI. Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation modifications in malignant melanoma. Eur J Nutr, 60(1): 147-158, 2021
2. Mitsiogianni M, Kyriakou S, Anestopoulos I, Trafalis DT, Deligiorgi MV, Franco R, Pappa A, Panayiotidis MI. An evaluation of the anti-carcinogenic response of major isothiocyanates in non-metastatic and metastatic melanoma cells. Antioxidants, 10(2): E284, 2021
3. Kyriakou S, Cheung W, Mantso T, Mitsiogianni M, Anestopoulos I, Veuger S, Trafalis DT, Franco R, Pappa A, Tetard D, Panayiotidis MI. A novel methylated analogue of L-Mimosine exerts therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma. Invest New Drugs, 39(4): 971-986, 2021
4. Mitsiogianni M, Anestopoulos I, Kyriakou S, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma. Invest New Drugs, 39(6): 1460-1468, 2021
5. Sagredou S, Dalezis P, Papadopoulou E, Voura M, Deligiorgi MV, Nikolaou M, Panayiotidis MI, Nasioulas G, Sarli V, Trafalis DT. Effects of a novel thiadiazole derivative with high anticancer activity on cancer cell immunogenic markers: mismatch repair system, PD-L1 expression, and tumor mutation burden. Pharmaceutics, 13(6): 885, 2021
6. Giatromanolaki A, Anestopoulos I, Panayiotidis MI, Mitrakas A, Pappa A, Koukourakis MI. Prognostic relevance of CD4/CD8/CD20 composition of tumor infiltrating lymphocytes in operable non-small cell lung cancer patients. Anticancer Res, 41(8): 3989-3995, 2021
7. Yiangou K, Kyriacou K, Kakouri E, Marcou Y, Panayiotidis MI, Loizidou MA, Hadjisavvas A, Michailidou K. Combination of a 15-SNP polygenic risk score and classical risk factors for the prediction of breast cancer risk in Cypriot women. Cancers, 13(18): 4568, 2021
8. Kyriakou S, Tragkola V, Plioukas M, Anestopoulos I, Chatzopoulou PS, Sarrou E, Trafalis DT, Deligiorgi MV, Franco R, Pappa A, Panayiotidis MI. Chemico-biological assessment of anticancer potency of Salvia Fruticosa extracts in an in vitro model of human malignant melanoma. Plants, 10(11): 2472, 2021
9. Petrakis G, Mantso T, Koukourakis MI, Panayiotidis MI, Botaitis S. Effectiveness of hyperthermia as a monotherapy and adjuvant therapy approaches against an in vitro model of colorectal carcinoma. Anticancer Res, 42(5): 2363-2374, 2022
10. Giatromanolaki A, Mitrakas A, Anestopoulos I, Kontosis A, Koukourakis IM, Pappa A, Panayiotidis MI, Koukourakis MI. Expression of CD47 and SIRPα macrophage immune-checkpoint pathway in non-small-cell lung cancer. Cancers, 14(7): 1801, 2022
11. Abdelaal G, Carter A, Panayiotides MI, Tetard D, Veuger S. Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines. Front Mol Biosci, 9:1005092, 2022
12. Spyridopoulou K, Kyriakou S, Nomikou A, Roupas A, Ermogenous A, Karamanoli K, Moyankova D, Djilianov D, Galanis A, Panayiotidis MI, Pappa A. Chemical profiling, antiproliferative and antimigratory capacity of Haberlea rhodopensis extracts in an in vitro platform of various human cancer cell lines. Antioxidants, 11(12): 2305, 2022
13- Figlioli G, Billaud A, Ahearn TU, Antonenkova AN, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blok MJ, Bogdanova NV, Bonanni, Brauch H, Burwinkel B, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chanock SJ, Chanock S, NBCS Collaborators, Czene K, Devilee P, Dörk T, Engel C, Eriksson M, Fasching PA, Figueroa JD, Gabrielson M, Gago-Dominguez M, García-Closas M, Giles GG, González-Neira A, Grassmann F, Guénel P, Gündert M, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Harrington PA, He W, Hillemanns P, Hollestelle A, Hooning MJ, Hoppe R, Howell A, Humphreys K, kConFab  Investigators, Jager A, Jakubowska A, Khusnutdinova EK, Ko Y-D, Kristensen VN, Lindblom A, Lissowska J, Lubiński  J, Mannermaa A, Margolin S, Mavroudis D, Newman WG, Obi N, Panayiotidis MI, Rashid MU, Rhenius V, Rookus MA, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sironen R, Suvanto M, Tollenaar Rob A.E.M, Tomlinson I, Truong T, van der Kolk LE, van Veen EM, Wappenschmidt B, Yang XR, Bolla MK, Dennis J, Dunning AM, Easton DF, Lush M, Michailidou K, Pharoah PDP, Wang Q, The BCAC Consortium, Adank MA, Schmidt MK, Andrulis IL, Chang-Claude J, Nevanlinna H, Chenevix-Trench G, Evans DG, Milne RL, Radice P, Peterlongo P. FANCM missense variants and breast cancer risk: a case-control association study on 75,156 European women. Eur J Hum Genet, 31(5): 578-587, 2023
14. Kyriakou S, Tragkola V, Paraskevaidis I, Plioukas M, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Chemical characterization and biological evaluation of Epilobium parviflorum extracts in an in vitro model of human malignant melanoma. Plants, 12(8): 1590, 2023

B. One Health Initiative

15. Theofilou SP, Antoniou C, Potamiti L, Hadjisavvas A, Panayiotidis M, Savva PG, Fotopoulos V, Costa CN. Immobilized Ag-nanoparticles for environmental applications: Elucidation of immobilized silver-induced inhibition mechanism of Escherichia coli. J Environ Chem Eng, 9: 106001, 2021
16. Richter J, Fanis P, Tryfonos C, Koptides D, Krashias G, Bashiardes S, Hadjisavvas A, Loizidou M, Oulas A, Alexandrou D, Kalakouta A, Panayiotidis MI, Spyrou GM, Christodoulou C. Molecular Epidemiology of SARS-CoV-2 in Cyprus. PLOS One, 16(7): e0248792, 2021
17. Krashias G, Deeba E, Costantinou A, Hadjiagapiou M, Koptides D, Richter J, Tryfonos C, Bashiardes S, Lambrianides N, Loizidou MA, Hadjisavvas A, Panayiotidis MI, Christodoulou C. Characterisation of IgG antibody response against Sars-CoV 2 (Covid-19) in the Cypriot population. Microorganisms, 10(1): 85, 2021

C. Circular Economy

18. Voulgaridou G-P, Mantso T, Anestopoulos I, Klavaris A, Katzastra C, Kiousi D-E, Mantela M, Galanis A, Gardikis K, Banat IM, Gutierrez T, Salek K, Euston SR, Panayiotidis MI, Pappa A. Toxicity profiling of biosurfactants produced by novel marine bacterial strains. Int J Mol Sci, 22(5): 2383, 2021
19. Kyriakou S, Tragkola V, Heba A, Anestopoulos I, Amery T, Stewart K, Winyard P, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Evaluation of bioactive properties of lipophilic fractions of edible and non-edible parts of Nasturtium officinale (watercress) in a model of human malignant melanoma cells. Pharmaceuticals, 15: 141, 2022
20. Kyriakou S, Michailidou K, Amery T, Stewart K, Winyard P, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Polyphenolic and glucosinolate profiling of aerial parts of Nasturtium officinale (Watercress). Front Plant Sci, 13:998755, 2022

D. Novel Engineered Materials

21. Lukose CC, Anestopoulos I, Mantso T, Bowen L, Panayiotidis MI, Birkett M. Thermal activation of Ti(1-x)Au(x) thin films with enhanced hardness and biocompatibility. Bioact Mater, 15: 426-445, 2022   
22. Lukose CC, Chavignon C, Mantso T, Panayiotidis MI, Birkett M. Enhanced mechanical and biocompatibility performance of Ti(1-x)Ag(x) coatings through intermetallic phase modification. Mater Charact, 194:112401, 2022
23. Abdul Wasy Zia, Anestopoulos I, Panayiotidis MI, Birkett M. Soft Diamond-like Carbon Coatings with Superior Biocompatibility for Medical Applications. Ceram Int, 49(11): 17203-17211, 2023
24. Abdul Wasy Zia, Anestopoulos I, Panayiotidis MI, Bowen L, Birkett M. Biomechanical characteristics of silver enriched diamond-like carbon coatings for medical applications. J Alloys Compd, 958: 170473, 2023
 

For a complete list of publications: https://pubmed.ncbi.nlm.nih.gov/?term=panayiotidis+m+&sort=date

Biography

• Professor, Department of Applied Sciences, Northumbria University, Newcastle Upon Tyne, UK (2016-2019)
• Professor & Chair (Nutrition & Toxicology), School of Life Sciences, Heriot Watt University, Edinburgh, Scotland, UK (2013-2016)
• Head of Human Health Department (by appointment), School of Life Sciences, Heriot Watt University, Edinburgh, Scotland, UK (2013-2016)
• Assistant Professor, Department of Pathological Anatomy, University of Ioannina, Medical School, Ioannina, Greece (2012-2013)
• Assistant Professor, School of Community Health Sciences, University of Nevada-Reno, Nevada, USA (2007-2009)
• Research Assistant Professor, Department of Nutrition, University of North Carolina-Chapel Hill, North Carolina, USA (2006-2007)
• IRTA Postdoctoral Fellow, Laboratory of Signal Transduction, NIEHS/NIH), Research Triangle Park, North Carolina, USA (2004)

My Linkedin profile: https://www.linkedin.com/in/michail-mihalis-panagiotidis-3b470226/